Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avita Medical has announced that the continuous manufacturing improvements yield significant margin expansion and generated a reduction of greater than 33% in cost of goods across company's product range.
Subscribe to our email newsletter
In July 2012 Avita Medical completed relocation of manufacture of its respiratory product line (Breath A Tech and Funhaler) to Guppy Plastics, located in Malaysia.
Avita has implemented a number of improvements to ReCell Spray-On Skin based on customer feedback, best manufacturing practises and component cost improvements.
Avita Medical CEO William Dolphin said the significant improvements to Avita’s products and manufacturing process have yielded important and quantifiable benefits in product quality, increased margins and reductions in operating costs.
"Moreover, the new manufacturing ensures ready availability of the ReCell Enzyme, a critical factor as demand for ReCell grows worldwide," Dolphin added.
"The company is committed to our Continuous Improvement model with tight control of our Quality and Manufacturing Systems a prerequisite for efficient operations."